Platelet Antibody Specificity Analyzed by Different Tests
|
By LabMedica International staff writers Posted on 09 Jun 2015 |
|
Image: Scanning electron micrograph of activated platelets (Photo courtesy of Bayer).
The detection of platelet antibodies plays a crucial role in the diagnosis of immunologic platelet disorders such as fetal/neonatal alloimmune thrombocytopenia (FNAIT) or refractoriness to platelet transfusions, influencing further therapeutic management.
The gold standard analysis for the determination of platelet antibodies, the “monoclonal antibody immobilization of platelet antigens” assay is restricted to specialized reference laboratories due to the laborious efforts involved and the consequent need for freshly prepared test platelet.
Hematologists at the Medical University of Graz (Austria) analyzed serum samples from 1,234 patients with a median age of 58.2 years and 573 were female and 661 male. The serum samples were tested for Human Leukocyte Antigen (HLA) or platelet-specific antibodies. The scientists routinely use two commercially available test methods, an antigen capture ELISA and a solid-phase assay. For the confirmation and specification of anti-HLA class I antibodies, a complement-dependent lymphocytotoxicity test is additionally performed.
All serum samples were analyzed by enzyme-linked immunosorbent assays (ELISA), either Lifecodes PAKPLUS or PAK12 (Gen-Probe; Waukesha, WI, USA), and by a solid-phase assay (Capture-P Ready Screen, Immucor Inc.; Norcross, GA, USA), and in specified cases by a specific lymphocytotoxicity test (LCT, Bio-Rad Medical Diagnostics GmbH; Dreieich, Germany). The LCT was performed in cases of clinically suspected or, by the described assays detected, HLA class I antibodies.
Platelet antibodies were detected in 366 of 1,234 samples (29.7%). In 70.3% concordant negative, but only in 8.4% concordant positive results were obtained with both the methods; 185 of 1,053 in the solid-phase assay negative samples were positive in the ELISA (15.0%). In samples positive in both methods, most antibodies reacted against HLA class I antigens. Glycoprotein (GP) specific platelet antibodies were more frequently detectable in the ELISA than in the solid-phase assay, whereas weakly positive results have to be interpreted cautiously.
The authors concluded that because ELISA, solid-phase assay, and LCT showed highly divergent results and only for detecting soluble platelet antibodies, and due to several limitations. The additional analysis by the “monoclonal antibody-specific immobilization of platelet antigen” (MAIPA) assay is highly recommended. The study was published on May 5, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Medical University of Graz
Gen-Probe
Immucor Inc.
 Reagent.jpg)
The gold standard analysis for the determination of platelet antibodies, the “monoclonal antibody immobilization of platelet antigens” assay is restricted to specialized reference laboratories due to the laborious efforts involved and the consequent need for freshly prepared test platelet.
Hematologists at the Medical University of Graz (Austria) analyzed serum samples from 1,234 patients with a median age of 58.2 years and 573 were female and 661 male. The serum samples were tested for Human Leukocyte Antigen (HLA) or platelet-specific antibodies. The scientists routinely use two commercially available test methods, an antigen capture ELISA and a solid-phase assay. For the confirmation and specification of anti-HLA class I antibodies, a complement-dependent lymphocytotoxicity test is additionally performed.
All serum samples were analyzed by enzyme-linked immunosorbent assays (ELISA), either Lifecodes PAKPLUS or PAK12 (Gen-Probe; Waukesha, WI, USA), and by a solid-phase assay (Capture-P Ready Screen, Immucor Inc.; Norcross, GA, USA), and in specified cases by a specific lymphocytotoxicity test (LCT, Bio-Rad Medical Diagnostics GmbH; Dreieich, Germany). The LCT was performed in cases of clinically suspected or, by the described assays detected, HLA class I antibodies.
Platelet antibodies were detected in 366 of 1,234 samples (29.7%). In 70.3% concordant negative, but only in 8.4% concordant positive results were obtained with both the methods; 185 of 1,053 in the solid-phase assay negative samples were positive in the ELISA (15.0%). In samples positive in both methods, most antibodies reacted against HLA class I antigens. Glycoprotein (GP) specific platelet antibodies were more frequently detectable in the ELISA than in the solid-phase assay, whereas weakly positive results have to be interpreted cautiously.
The authors concluded that because ELISA, solid-phase assay, and LCT showed highly divergent results and only for detecting soluble platelet antibodies, and due to several limitations. The additional analysis by the “monoclonal antibody-specific immobilization of platelet antigen” (MAIPA) assay is highly recommended. The study was published on May 5, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Medical University of Graz
Gen-Probe
Immucor Inc.
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data
Channels
Clinical Chemistry
view channel
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more
Molecular Diagnostics
view channel
Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
Two studies have identified proteins in the blood that could potentially alert individuals to the presence of cancer more than seven years before the disease is clinically diagnosed. Researchers found... Read more (1)_1.jpg "Image: Ultrasound image of micro-histotripsy liberation of biomarkers in a tumor (Photo courtesy of Joy Wang and Pradyumna Kedarisetti)"){kind=small}
Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
Ultrasound imaging serves as a noninvasive method to locate and monitor cancerous tumors effectively. However, crucial details about the cancer, such as the specific types of cells and genetic mutations... Read more_1.jpg "Image: The innovative method to customize and strengthen DNA origami structure promises breakthroughs in medicine (Photo courtesy of Shutterstock)")
.jpg "Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)")
Immunology
view channel.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read moreMicrobiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
Rapid and accurate intraoperative diagnosis is essential for tumor surgery as it guides surgical decisions with precision. Traditional intraoperative assessments, such as frozen sections based on H&E... Read more
HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
Annually, over 604,000 women across the world are diagnosed with cervical cancer, and about 342,000 die from this disease, which is preventable and primarily caused by the Human Papillomavirus (HPV).... Read more
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue.... Read more
Technology
view channel
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
